Cefovecin

From Dog
Cefovecin.jpg

Cefovecin (Convenia®) is a new third generation cephalosporin antibiotic indicated for the treatment of bacterial skin diseases such as gingivitis, superficial pyoderma[1], subcutaneous infections (deep pyoderma)[2], cellulitis and abscesses[3] in dogs, caused by aerobic and anaerobic gram negative and gram positive bacteria[4].

Cefovecin is bactericidal against Staphylococcus pseudintermedius[5] and Streptococcus spp, Escherichia coli, Pasteurella multocida, Klebsiella spp and Proteus spp, but is not active against Pseudomonas spp or Enterococcus spp[6]. It is also effective against Bordetella spp, the causative organism of canine infectious tracheobronchitis[7].

Cefovecin has been formulated as an extended-spectrum cephalosporin solution containing 80 mg/ml cefovecin sodium, allowing extended therapeutic concentrations when given at 14-day intervals[8]. It has a long half-life of 6.9 days and demonstrates prolonged concentrations in extracellular fluid allowing for dosing every 14 days. If required, the dose of 8 mg/kg subcutaneously in cats can be repeated every 14 days for a total of three doses. Cefovecin is eliminated through renal excretion with up to 25% biliary excretion, allowing it to be used in renal infections, prostatitis and cystitis[9].

Cefovecin should not be given to animals allergic to penicillins or cephalosporins, less than 8 weeks old, if they are pregnant or lactating, or have severe renal dysfunction.

Cefovecin was shown to be as effective as amoxicillin/clavulanate administered orally in the treatment of bacterial skin infections. Cefovecin offers the additional benefit of eliminating owner non-compliance.

The recommended dose for Cefovecin in cats is 8 mg/kg (0.1cc/kg) subcutaneously every 2 weeks for 3 doses.

References

  1. Van Vlaenderen I et al (2011) Estimation of the clinical and economic consequences of non-compliance with antimicrobial treatment of canine skin infections. Prev Vet Med 99(2-4):201-210
  2. Stegemann MR et al(2007) Clinical efficacy and safety of cefovecin in the treatment of canine pyoderma and wound infections. J Small Anim Pract 48(7):378-386
  3. Six R et al (2008) Efficacy and safety of cefovecin in treating bacterial folliculitis, abscesses, or infected wounds in dogs. J Am Vet Med Assoc 233(3):433-439
  4. Matousek, JL (2003) Infectious skin diseases. In Morgan, RV, Bright MR & Swartout, MS: Handbook of Small Animal Practise. 4th Edn. WB Saunders, Philadelphia. pp:842-857
  5. Westermeyer R et al (2010) In Vitro Comparison of Staphylococcus pseudintermedius Susceptibility to Common Cephalosporins Used in Dogs. Vet Ther 11(3):E1-9
  6. Stegemann, M. et al (2007) The efficacy and safety of cefovecin in the treatment of feline abscesses and infected wounds. J Small Anim Pract 48(12):683-89
  7. Murphy CP et al (2012) Out-patient antimicrobial drug use in dogs and cats for new disease events from community companion animal practices in Ontario. Can Vet J 53(3):291-298
  8. Stegemann MR et al (2006) Pharmacokinetics and pharmacodynamics of cefovecin in dogs. J Vet Pharmacol Ther 29(6):501-511
  9. Passmore CA et al (2007) Efficacy and safety of cefovecin (Convenia) for the treatment of urinary tract infections in dogs. J Small Anim Pract 48(3):139-144